Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acebilustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H known ✓ | P09960 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acebilustat SCHEMBL16149196 | 1.00 | LTA4H (1.00) | LTA4H | |
| SCHEMBL17557092 | 0.94 | LTA4H (0.89) | LTA4H | |
| SCHEMBL5310528 | 0.91 | LTA4H (0.82) | LTA4H | |
| SCHEMBL3035664 | 0.89 | LTA4H (0.81) | LTA4H | |
| SCHEMBL17563464 | 0.85 | LTA4H (0.74) | LTA4H | |
| SCHEMBL3036309 | 0.84 | LTA4H (0.80) | LTA4H | |
| SCHEMBL3045086 | 0.82 | LTA4H (0.77) | LTA4H | |
| SCHEMBL3045836 | 0.81 | LTA4H (0.68) | LTA4H | |
| SCHEMBL3043482 | 0.81 | LTA4H (0.67) | LTA4H | |
| SCHEMBL3032189 | 0.80 | LTA4H (0.78) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724069-A2 | METHODS OF TREATING LIPEDEMA AND LYMPHATIC DISEASE OF THE SUBCUTANEOUS TISSUE | Celltaxis, LLC (US) | 2026-04-15 | — | — | EP | claimed |
| US-12558353-B2 | Method of reducing pulmonary exacerbations in respiratory disease patients | CELLTAXIS, LLC (US) | 2026-02-24 | — | — | US | claimed |
| US-20250114430-A1 | MODIFIED PEPTIDOMIMETICS AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-04-10 | — | — | US | claimed |
| EP-3801559-B1 | METHOD OF REDUCING PULMONARY EXACERBATIONS IN RESPIRATORY DISEASE PATIENTS | CELLTAXIS LLC (US) | 2025-01-01 | — | — | EP | claimed |
| WO-2024254377-A2 | METHODS OF TREATING LIPEDEMA AND LYMPHATIC DISEASE OF THE SUBCUTANEOUS TISSUE | CELLTAXIS, LLC (US) | 2024-12-12 | — | — | WO | claimed |
| US-20240398793-A1 | Methods of Treating Lymphedema | CELLTAXIS LLC (US) | 2024-12-05 | — | — | US | claimed |
| US-20240358699-A1 | METHOD OF REDUCING PULMONARY EXACERBATIONS IN RESPIRATORY DISEASE PATIENTS | CELLTAXIS LLC (US) | 2024-10-31 | — | — | US | claimed |
| EP-4444419-A2 | METHODS OF TREATING LYMPHEDEMA | Celltaxis, LLC (US) | 2024-10-16 | — | — | EP | claimed |
| US-20240182523-A1 | MODIFIED PEPTIDOMIMETICS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-06 | — | — | US | claimed |
| EP-4314010-A1 | MODIFIED PEPTIDOMIMETICS AND METHODS OF USE | The University of North Carolina at Chapel Hill (US) | 2024-02-07 | — | — | EP | claimed |
| US-20200138791-A1 | METHODS OF INHIBITING LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2020-05-07 | — | — | US | claimed |
| US-10350197-B2 | Methods of inhibiting leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2019-07-16 | — | — | US | claimed |
| US-20180117014-A1 | METHODS OF INHIBITING LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-05-03 | — | — | US | claimed |
| US-9820974-B2 | Methods of inhibiting leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2017-11-21 | — | — | US | claimed |
| EP-1976828-B1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2016-12-21 | — | — | EP | claimed |
| US-20160067226-A1 | METHODS OF INHIBITING LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2016-03-10 | — | — | US | claimed |
| US-8569303-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2013-10-29 | — | — | US | claimed |
| US-7737145-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | ESTRELLITA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | claimed |
| EP-1976828-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Schering Aktiengesellschaft (DE) | 2008-10-08 | — | — | EP | claimed |
| WO-2007079078-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10350197-B2 | Methods of inhibiting leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R | LTA4H 1/4885 |
| US-20160067226-A1 | METHODS OF INHIBITING LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | LTA4H 1/4885 |
| US-20240398793-A1 | Methods of Treating Lymphedema | LTB4R, LTA4H, LTB4R2 | LTA4H 2/4885 |
| US-12558353-B2 | Method of reducing pulmonary exacerbations in respiratory disease patients | SERPINB1, CFTR, LTA4H | LTA4H 3/4885 |
| US-20180117014-A1 | METHODS OF INHIBITING LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | LTA4H 1/4885 |
| US-20200138791-A1 | METHODS OF INHIBITING LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | LTA4H 1/4885 |
| US-20240358699-A1 | METHOD OF REDUCING PULMONARY EXACERBATIONS IN RESPIRATORY DISEASE PATIENTS | LTA4H, LTB4R2, LTC4S | LTA4H 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.